tbuckley/cabot-search huggingface dataset:
Quality of life following amputation or limb salvage in patients with lower extremity sarcoma
Authors: G. E. Mason, L. Aung, S. Gall, P. A. Meyers, C. Sklar, R. Butler, J. H. Healey, R. G. Gorlick
Journal: Journal of Clinical Oncology (2007)

19530 Background: Currently between 80–90% of patients with lower extremity sarcoma undergo limb salvage procedures. A few trials show that the functional quality of life is significantly higher for limb salvage surgery compared to patients with amputation. While taking quality of life and psychological consequences into account it would seem that limb salvage would be the procedure of preference; however, this difference has yet to be demonstrated in previous studies. Methods: Eighty-two long-term survivors of lower extremity sarcoma were studied to make a comparison of the overall quality of life in limb salvage and amputation patients. Forty-eight patients with limb salvage (age 14–49 years) and thirty-four patients with amputations (age 15–49 years) were studied who were at least one-year post- surgical procedure. Sensitive psychometric measures such as self-report questionnaires and visual analog scales were used to assess psychological consequences and quality of life. Results: The overall quality of life of patients with the limb salvage was significantly higher than patients with amputation (p-value &lt; 0.01). For the quality of life questionnaire, the limb salvage patients had a higher mean value in every domain except parent-child relations. The domains that showed a significant difference between patients with limb salvage and patients with amputations are material well being, occupational relations, creative-aesthetic behavior, and sports activity. Conclusions: For patients with lower extremity sarcoma, the psychological quality of life is better for those who received the limb salvage procedure. The significance of this study is that it one of the first to show that there is a direct benefit to limb salvage surgery as compared to amputation in regards to several psychological factors and total quality of life. No significant financial relationships to disclose.
Feasibility and safety of endoscopic submucosal dissection for lesions involving the ileocecal valve
Authors: Tetsuya Yoshizaki, Takashi Toyonaga, Shinwa Tanaka, Yoshiko Ohara, Fumiaki Kawara, Shinichi Baba, Eiji Tsubouchi, Hiroshi Takihara, Daisuke Watanabe, Tsukasa Ishida, Namiko Hoshi, Yoshinori Morita, Eiji Umegaki, Takeshi Azuma
Journal: Endoscopy (2016)

<b>Background and study aim: </b>Endoscopic submucosal dissection (ESD) has been applied to treat early colorectal cancers. The aim of this study was to clarify the clinical course of ESD for lesions involving the ileocecal valve (ICV) by evaluating the successful resection rates, and the risk and frequency of adverse events. <b>Patients and methods: </b>The outcome of ESD on 38 ICV lesions was compared with the outcome of 132 cecal lesions that did not involve the ICV or appendiceal orifice during the same study period. The factors related to longer procedure time, postoperative stricture development, and tumor recurrence were investigated for ESD of ICV lesions. <b>Results: </b>There was no significant difference between the ICV and non-ICV groups in the en block resection rates. The median procedure time was significantly longer in the ICV group than in the non-ICV group, with a point estimate of the difference of 37 minutes (95 % confidence interval [CI] 20.00 to 56.00; <i>P </i> < 0.01). None of the patients developed symptomatic post-ESD stricture or tumor recurrence. ESD procedure duration was ≥ 120 minutes in 16 lesions and < 120 minutes in 22 lesions of the ICV group. A specimen diameter of ≥ 40 mm and tumor extension into terminal ileum were factors related to a longer procedure time (odds ratio [OR] 8.40, 95 %CI 1.53 to 46.10, <i>P</i> = 0.01; OR 10.60, 95 %CI 2.17 to 51.40, <i>P </i> < 0.01, respectively). <b>Conclusions: </b>ICV lesions can be resected by ESD without major adverse events or causing symptomatic stricture development. However, ESD for ICV lesions should be performed only by expert endoscopists, as the procedure requires accomplished endoscopic skill and experience.
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
Authors: Peter Schmid, Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zammit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah-Jalal Sarker, Louise Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Mark R. Lackner, Mika Derynck, Timothy R. Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alastair Thompson
Journal: Journal of Clinical Oncology (2016)

Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy.In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to 2 weeks of preoperative treatment with anastrozole 1 mg once per day (n = 26) or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49). The primary end point was inhibition of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment.There was significantly greater geometric mean Ki-67 suppression of 83.8% (one-sided 95% CI, ≥ 79.0%) for the combination and 66.0% (95% CI, ≤ 75.4%) for anastrozole (geometric mean ratio [combination:anastrozole], 0.48; 95% CI, ≤ 0.72; P = .004). PIK3CA mutations were not predictive of response to pictilisib, but there was significant interaction between response to treatment and molecular subtype (P = .03); for patients with luminal B tumors, the combination:anastrozole geometric mean ratio of Ki-67 suppression was 0.37 (95% CI, ≤ 0.67; P = .008), whereas no significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98). Multivariable analysis confirmed Ki-67 response to the combination treatment of patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression.Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.
Plasma kinetics and uptake of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate by neoplastic ovarian tissues
Authors: C. H. Azevedo, J. P. Carvalho, C. J. Valduga, D. G. Rodrigues, D. C. Fernandes, R. Egg, R. C. Maranhão
Journal: Journal of Clinical Oncology (2004)

3176 Background: Previously we showed that etoposide oleate (ETO)associated with a cholesterol-rich microemulsion (LDE) forms a stable complex that is taken up by malignant cells. LDE-ETO retains the in vitro anti-proliferative activity of the drug and markedly reduces the toxicity to animals. In this study, the plasma kinetics of LDE:ETO and the ability of the complex to concentrate in the tumor after injection into the patients were tested. Methods: LDE-ETO labeled with [3H]etoposide oleate and [14C]-Cholesteryl Oleate (CO) was intravenously injected into 10 patients with ovarian cancer (50,6 ± 7,5 yr.) 24 h before the surgery. Blood samples were collected over the 24 h period to determine the plasma decay curves of the complex labels. Radioactivity present in plasma aliquots was determined in a scintillation solution and the plasma fractional clearance rate (FCR) was calculated by compartmental analysis. Specimens of tumors and normal ovaries excised during the surgery were collected for lipid extraction, separation by thin layer chromatography and radioactive counting. Results: FCR of LDE and of the drug were similar (0,0881 e 0,1722, respectively, p = 0.0653). The mean uptake of both [14C]-LDE and [3H]-etoposide oleate by malignat tissue of ovary was three fold greater when compared with that of the normal contralateral normal ovaries (LDE uptake = 448 ± 184 and 143 ± 51 and etoposide oleate uptake = 346 ± 75 and 103 ± 56, respectively). Conclusions: Our results indicate that most of the drug remains associated with LDE particles while in the circulation and that LDE has the hability to target etoposide oleate to the malignant ovarian tissues. Thus, LDE-ETO is an interesting preparation for testing in clinical trials. No significant financial relationships to disclose.
Immune complex binding by Fcγ receptor IIA and regulation of inflammation
Authors: Aikaterini Bazakou, John Greenman, Simon Hart
Journal: European Respiratory Journal (2011)

Immune complexes, mainly associated with autoimmune diseases, may also be present in the blood and lung during respiratory diseases including bacterial pneumonia and ARDS. However, the precise pathogenic role of immune complexes in these conditions is unclear.  Binding of immune complexes to the uniquely human stimulatory IgG receptor FcγRIIA is constitutively suppressed on neutrophils and macrophages. Elucidating the mechanism behind this suppression will help us understand how the body regulates its response immune complexes.  The erythroleukaemia cell line K562 that expresses the FcγIIA inherently and exhibits FcγRIIA suppression was used as a model. The effects of microbial neuraminidases on immune complex binding by the FcγRIIA were tested by flow cytometry. We also investigated whether there is a protein in close proximity to FcγRIIA that could potentially block its IgG binding site by protein cross-linking. Lastly, the stimulatory character of the receptor was explored by calcium signalling.  Although the receptor exhibits suppressed immune complex binding, microbial neuraminidases can significantly augment the ability of the FcγRIIA to bind immune complexes. The cross-linking experiments reveal that there is a protein in close proximity with FcγRIIA that could be blocking its IgG binding site under basal conditions. Finally, while FcγRIIA exhibits limited binding of immune complexes in its native state, the stimulatory signals produced by the receptor on contact with immune complexes are significantly strong.  Understanding how the body regulates immune complexes could lead to identification of novel methods for both activating and inhibiting the progression of immune complex mediated inflammation.
Extramedullary Involvement of Mast Cell Leukemia Detected by 18F-FDG PET/CT
Authors: Zhanli Fu, Jin Zhang, Meng Liu, Ziao Li, Qian Li
Journal: Clinical Nuclear Medicine (2016)

Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis, characterized by the leukemic expansion of immature mast cells. We present a case of MCL with extramedullary involvement of cervical lymph node and lung demonstrated by the initial F-FDG PET/CT scan. After a transient complete remission by induction chemotherapy and allogeneic hematopoietic stem cell transplantation, the follow-up PET/CT showed extensive extramedullary relapse involving multiple lymph nodes and small bowel. F-FDG PET/CT may be a useful tool to comprehensively stage and follow-up MCL.
Abstract 15884: A Simple Anatomical Index Predicting the Patients Suitable for Catheter Ablation of Atrial Fibrillation
Authors: kunihiko kiuchi, akihiro yoshida, asumi takei, mitsuaki itoh, kimitake imamura, ryudou fujiwara, atsushi suzuki, tomoyuki nakanishi, soichiro yamashita, akinori matsumoto, ken-ichi hirata
Journal: Circulation (2012)

INTRODUCTON: We had previously reported that the shorter distance of mitral isthmus, between RIPV and mitral annulus and the larger cross-sectional area of RSPV were associated with AF elimination ...
Abstract 12880: Up-Regulation of Microrna-208b Contributes to Diabetic Myocardial Fibrosis in Mouse
Authors: Zhi Xin Shan, Lin lin Guo, Jie ning Zhu, Qiu xiong Lin, Chun yu Deng, Xiao Zou, Ye you Liang, Wen si Zhu, Xi yong yu, Shu lin Wu
Journal: Circulation (2014)

MicroRNAs play important roles in myocardial fibrosis during diabetic cardiomyopathy. The present study aimed to investigate the role of microRNA-208b (miR-208b) in diabetic myocardial fibrosis. Compared to the db/m control mice, Smad3 was activated , fibrosis-related genes expression were significantly up-regulated, and miRNAs were dysregulated in the myocardium of the 16-week-old diabetic db/db mice. miR-208b was confirmed up-regulated in the db/db diabetic myocardium in vivo and in mouse cardiomyocytes and cardiac fibroblasts after treatment with Ang-II, TGF-β and high glucose/glucose oxidase (HG/Go) in vitro , respectively. By using recombinant adenovirus expressing CD63-GFP, rAd-CD63-GFP, we infected neonatal mouse cardiomyocytes with rAd-CD63-GFP and tracked the secreted exosomes with GFP. We found that miR-208b was increased in the secreted exosomes from HG/Go-treated cardiomyocytes, and the exosomes with increased miR-208b could enhance fibrosis associated Col1a1, α-SMA and CTGF expressions in cardiac fibroblasts. Transfection of miR-208b mimic could increase Col1a1, α-SMA and CTGF expression in a dose-dependent manner in cardiac fibroblasts. However, blockage of miR-208b could inhibit fibrosis related genes expression. Mtf2 and Pgrmc1 were verified modulated by miR-208b at post transcriptional level in vitro . Consistently, Mtf2 and Pgrmc1 expressions were decreased in the diabetic myocardium, and knockdown of Mtf2 or Pgrmc1could increase fibrosis related genes expression in cardiac fibroblasts. Smad3 inhibitor, Naringenin, could dramatically inhibit miR-208b expression in cardiac fibroblasts. Taken together, we demonstrated that miR-208b was up-regulated in diabetic fibrotic myocardium, Mtf2 and Pgrmc1 mediated the effect of miR-208b on enhancing Col1a1, α-SMA and CTGF expression in diabetic myocardial fibrosis.
Unusual Sites of Involvement in Non-Hodgkin's Lymphoma
Authors: S. Aloulou, J. Bosq, D. Vanel, V. Ribrag
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.21.4395 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12409340 Unusual Sites of Involvement in Non-Hodgkin's Lymphoma Case 2. Isolated Meningeal Anaplastic Large-Cell Lymphoma S. AloulouxS. AloulouSearch for articles by this author , J. BosqxJ. BosqSearch for articles by this author , D. VanelxD. VanelSearch for articles by this author , V. RibragxV. RibragSearch for articles by this author Show More Institut Gustave-Roussy, Villejuif, France https://doi.org/10.1200/JCO.2002.20.21.4395 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).
Authors: Hisham Mohamed Mehanna, Wai Lup Wong, Christopher C McConkey, Joy K Rahman, Max Robinson, Andrew G. J. Hartley, Christopher Nutting, Ned Powell, H Al-Booz, Martin Robinson, Elizabeth Junor, Claire Hulme, Alison Florence Smith, Peter Hall, Janet Dunn
Journal: Journal of Clinical Oncology (2015)

6009 Background: Planned ND after radical CRT for LANM remains controversial. 30% of ND specimens show histological evidence of tumour, albeit tumour viability cannot be confirmed. Consequently, many clinicians still practice planned ND. In mainly retrospective single-institution studies, FDG-PETCT demonstrated high negative predictive values for persistent nodal disease, providing a possible alternative paradigm to ND. This study aimed to determine the efficacy and cost-effectiveness of PETCT guided surveillance, compared to planned ND, in a multicentre randomised setting. Methods: Eligibility: Patients with LANM of oro-, hypo-pharynx, larynx, oral or occult HNSCC receiving CRT and fit for ND. Randomisation (1:1): to planned ND before or after CRT (control), or CRT followed by FDG-PETCT 10-12 weeks post CRT with ND only if PETCT showed incomplete or equivocal response of nodal disease (intervention). Balanced by centre, planned ND timing, CRT schedule, disease site, T / N stage. Primary outcome: Overall Survival (OS), minimum follow-up 2 years. Analysis:560 patients needed to detect non-inferior OS in the intervention arm with 80% power, Type I error 5%, defining non-inferiority as having a hazard ratio (HR) no higher than 1.50. Intention to treat analysis was performed by Cox proportional hazards model. Results: 564 patients recruited (282 ND arm, 282 surveillance arm; 17% N2a, 61% N2b, 18% N2c, 3% N3). 84% had oropharyngeal cancer. 75% of tested cases were p16+ve. Median follow-up 36 months. The HR for OS was 0.92 (95% CI: 0.65, 1.32) indicating non-inferiority. HR margin of 1.50 lies at the 99.6 percentile of this estimate, p = 0.004. There were no differences by p16 status. There were 54 NDs performed in the surveillance arm with 22 surgical complications; 221 NDs in the ND arm with 85 complications. Conclusions: PETCT guided active surveillance showed similar survival outcomes to ND arm, but resulted in considerably fewer NDs, and fewer complications, supporting its use in routine practice. Clinical trial information: 13735240.
Modulation by Retinoic Acid of Cellular, Surface-Exposed, and Secreted Glycoconjugates in Cultured Human Sarcoma Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: L Meromsky, R Lotan
Journal: JNCI Journal of the National Cancer Institute (1984)

The effect of beta-all-trans-retinoic acid (RA) on the synthesis of cellular, cell surface, and secreted glycoconjugates by human Hs705 chondrosarcoma and Hs791 osteosarcoma cells was investigated in vitro. Untreated and RA-treated cells were labeled either metabolically with radioactive precursors or by oxidation of externally exposed cell membrane glycoprotein(s) (GP) by treatment with NalO4 or neuraminidase and galactose oxidase followed by reduction with NaB[3H]4. The cells were solubilized and analyzed by polyacrylamide gel electrophoresis followed by fluorography. RA enhanced the labeling of sialic acid and galactose residues on the GP of relative molecular weight(s) (Mr) in the range 95,000-300,000 on the surfaces of both cell types. [3H]glycosamine incorporation into GP with Mr of 100,000, 150,000, and 190,000 in both cell lines was also stimulated. In the Hs705 cells there was also an increase in the labeling of a 290,000-Mr GP. In contrast, [3H]glucosamine incorporation into glycoconjugates greater than 400,000 Mr in both the cells and the conditioned medium of Hs705 cells decreased. The latter glycoconjugates were susceptible to hyaluronidase and chondroitinases. [3H]glucosamine incorporation into a secreted 230,000-Mr GP, identified as fibronectin, was also reduced. Analyses of conditioned media of cells labeled with [35S]methionine or [14C]proline demonstrated that RA decreased the secretion of procollagen chains and fibronectin. Immunofluorescence revealed that RA alters the distribution of cell-associated fibronectin. These results demonstrated that RA increases the glycosylation of specific cellular and cell surface GP and decreases the production of secreted GP and glycosaminoglycans by the sarcoma cells.
Updating the Toxic Substances Control Act to Protect Human Health
Authors: Leonardo Trasande
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075
Authors: Gaëlle Labouré, Marie-Cécile Parrens, Anjarasoa Tsaranazy, Magali Bordier, Steven Le Gouill, Vincent Delwail, Remy Gressin, Jérôme Cornillon, Gandhi Damaj, Charles Yves Foussard, Herve Maisonneuve, Eric Deconinck, Guillaume Cartron, Francois Dreyfus, Emmanuel Gyan, Laurent Sutton, Nadine Morineau, Magda Alexis, Anne Banos, Diane Damotte, Anne Moreau, Françoise Kraeber-Bodéré, Delphine Rossille, Thierry Fest, Thierry Lamy, Noel Milpied
Journal: Blood (2015)
Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy
Authors: Dafeng Chu, Qi Zhao, Jian Yu, Faya Zhang, Hui Zhang, Zhenjia Wang
Journal: Advanced Healthcare Materials (2016)

Cancer immunotherapy using tumor-specific monoclonal antibodies presents a novel approach for cancer treatment. A monoclonal antibody TA99 specific for gp75 antigen of melanoma initiates neutrophil recruitment in tumor responsible for cancer therapy. Here, a strategy is reported for hijacking neutrophils in vivo using nanoparticles (NPs) to deliver therapeutics into tumor. In a mouse model of melanoma, it is shown that systemically delivered albumin NPs increase in tumor when TA99 antibody is injected; and the NP tumor accumulation is mediated by neutrophils. After the administration of pyropheophorbide-a loaded albumin NPs and TA99, photodynamic therapy significantly suppresses the tumor growth and increases mouse survival compared with treatment with the NPs or TA99. The study reveals a new avenue to treat cancer by NP hitchhiking of immune systems to enhance delivery of therapeutics into tumor sites.
<italic>Brief Communication:</italic> Guinea Pig Tumor-Specific Natural Antibodies in Normal Rabbit Sera
Authors: T Borsos, S H Oanian
Journal: JNCI Journal of the National Cancer Institute (1974)

Sera of 5 unimmunized rabbits were tested for complement-fixing antibodies to guinea pig tumor cells. With the sensitive C1 fixation test, some sera proved to contain antibodies able to distinguish between the antigenically distinct cells of the tumor lines.
Obesity may increase risk of rare type of stroke in women taking oral contraceptives
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Obese women who use oral contraceptives seem to have a raised risk of a rare type of stroke known as a cerebral venous thrombosis (CVT), a study published online by JAMA Neurology shows.1

CVT affects mainly young adults and children and is associated with specific risk factors including local infections and head trauma, as well as some of the same risk factors as venous thromboembolism, such as cancer and oral contraceptive use. However, the effect of …